News | July 04, 2025
Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
mRNA-1010 demonstrated superior relative vaccine efficacy
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The company received seven observations in the Form-483
Subscribe To Our Newsletter & Stay Updated
